CymaBay Therapeutics (Nasdaq:CBAY) - Cotización, noticias y análisis

Resumen de acción CBAY

CymaBay Therapeutics, Inc. es una empresa biofarmacéutica en fase clínica centrada en el desarrollo y suministro de terapias para tratar enfermedades hepáticas y otras enfermedades crónicas.

Acerca de la empresa

CBAY fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	2/6
Past Performance	0/6
Financial Health	4/6
Dividends	0/6

Recompensas

Cotiza un 86.9% por debajo de nuestra estimación de su valor justo

Se prevé un crecimiento anual de los ingresos de 50.87%

Análisis de riesgos

Los accionistas han sido diluidos en el último año

Actualmente no es rentable y no se prevé que lo sea en los próximos 3 años

Competidores de CymaBay Therapeutics, Inc.

Axsome Therapeutics

NasdaqGM:AXSM

US$3.5b

Intra-Cellular Therapies

NasdaqGS:ITCI

US$7.6b

Arvinas

NasdaqGS:ARVN

US$2.2b

SNDL

NasdaqCM:SNDL

US$649.8m

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for CymaBay Therapeutics
Historical stock prices
Current Share Price	US$32.48
52 Week High	US$32.50
52 Week Low	US$7.26
Beta	0.32
1 Month Change	0.87%
3 Month Change	40.67%
1 Year Change	262.91%
3 Year Change	607.63%
5 Year Change	147.94%
Change since IPO	260.89%

Noticias y actualizaciones recientes

CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Analysts Just Slashed Next Year's Revenue Estimates By 17%

Feb 15

Recent updates

CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Analysts Just Slashed Next Year's Revenue Estimates By 17%

Feb 15

Analysts' Revenue Estimates For CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Are Surging Higher

Dec 22

Rentabilidad de los accionistas

	CBAY	US Pharmaceuticals	Mercado US
7D	0.03%	0.3%	2.2%
1Y	262.9%	9.8%	22.8%

Rentabilidad vs. Industria: CBAY superó al sector US Pharmaceuticals , que obtuvo un rendimiento del 9.7% el año pasado.

Rentabilidad vs. Mercado: CBAY superó al mercado US, que obtuvo un rendimiento del 19.3% el año pasado.

Volatilidad de los precios

Is CBAY's price volatile compared to industry and market?
CBAY volatility
CBAY Average Weekly Movement	8.2%
Pharmaceuticals Industry Average Movement	10.0%
Market Average Movement	6.0%
10% most volatile stocks in US Market	16.5%
10% least volatile stocks in US Market	3.0%

Precio estable de las acciones: El precio de las acciones de CBAY ha sido volátil en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de CBAY (8%) se ha mantenido estable durante el año pasado.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
1988	101	Sujal Shah	www.cymabay.com

CymaBay Therapeutics, Inc. es una empresa biofarmacéutica en fase clínica centrada en el desarrollo y suministro de terapias para tratar enfermedades hepáticas y otras enfermedades crónicas. Su principal producto candidato es seladelpar (MBX-8025), un agonista selectivo del receptor delta activado por el proliferador de peroxisomas para el tratamiento de la colangitis biliar primaria (CBP). La empresa también desarrolla MBX-2982, un agonista del receptor 119 acoplado a proteína G (GPR119), en sujetos con diabetes de tipo 1.

Resumen de fundamentos de CymaBay Therapeutics, Inc.

¿Cómo se comparan los beneficios e ingresos de CymaBay Therapeutics con su capitalización de mercado?
Estadísticas fundamentales de CBAY
Capitalización bursátil	US$3.73b
Beneficios(TTM)	-US$105.37m
Ingresos (TTM)	US$31.07m

120.0x

Ratio precio-ventas (PS)

-35.4x

Ratio precio-beneficio (PE)

¿Está CBAY sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de CBAY
Ingresos	US$31.07m
Coste de los ingresos	US$80.80m
Beneficio bruto	-US$49.73m
Otros gastos	US$55.64m
Beneficios	-US$105.37m

Últimos beneficios comunicados

Dec 31, 2023

Próxima fecha de beneficios

n/a

Beneficios por acción (BPA)	-0.92
Margen bruto	-160.03%
Margen de beneficio neto	-339.10%
Ratio deuda/patrimonio	37.4%

¿Cómo se ha desempeñado CBAY a largo plazo?

Ver rendimiento histórico y comparativa

Resumen de acción CBAY

Recompensas

Análisis de riesgos

Competidores de CymaBay Therapeutics, Inc.

NasdaqGM:AXSM

US$3.5b

NasdaqGS:ITCI

US$7.6b

NasdaqGS:ARVN

US$2.2b

NasdaqCM:SNDL

US$649.8m

Historial de precios y rendimiento

Noticias y actualizaciones recientes

CymaBay Therapeutics Files Form 15

Gilead Sciences, Inc. (NasdaqGS:GILD) completed the acquisition of CymaBay Therapeutics, Inc. (NasdaqGS:CBAY).

President exercised options to buy US$4.5m worth of stock.

CymaBay Therapeutics, Inc. Announces European Medicines Agency Accepts for Review the Marketing Authorization Application for Seladelpar for the Treatment of Primary Biliary Cholangitis

No longer forecast to breakeven

CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Analysts Just Slashed Next Year's Revenue Estimates By 17%

Recent updates

CymaBay Therapeutics Files Form 15

Gilead Sciences, Inc. (NasdaqGS:GILD) completed the acquisition of CymaBay Therapeutics, Inc. (NasdaqGS:CBAY).

President exercised options to buy US$4.5m worth of stock.

CymaBay Therapeutics, Inc. Announces European Medicines Agency Accepts for Review the Marketing Authorization Application for Seladelpar for the Treatment of Primary Biliary Cholangitis

No longer forecast to breakeven

CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Analysts Just Slashed Next Year's Revenue Estimates By 17%

Price target increased by 8.5% to US$31.07

CymaBay Announces FDA Acceptance of NDA and Priority Review for Seladelpar for the Treatment of Primary Biliary Cholangitis

CymaBay Therapeutics, Inc. Announces Executive Changes

Forecast to breakeven in 2026

Analysts' Revenue Estimates For CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Are Surging Higher

Cymabay Therapeutics, Inc. and Lewis Stuart, Chief Commercial Officer, Mutually Agrees on Cease to Be an Officer and Employee Effective December 29, 2023

Cymabay Therapeutics, Inc. Submits New Drug Application to FDA for Seladelpar for the Treatment of Primary Biliary Cholangitis

President exercised options and sold US$973k worth of stock

President notifies of intention to sell stock

Price target increased by 7.5% to US$24.82

New minor risk - Profitability

CymaBay Therapeutics, Inc. Announces Publication of Two-Year Safety and Efficacy Results of Seladelpar in Patients with Primary Biliary Cholangitis

CymaBay Therapeutics, Inc. to Report Q3, 2023 Results on Nov 07, 2023

President exercised options and sold US$597k worth of stock

General Counsel notifies of intention to sell stock

CymaBay Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $224.999939 million.

Price target increased by 17% to US$21.27

Insider notifies of intention to sell stock

Consensus revenue estimates increase by 156%

Price target increased by 8.0% to US$17.64

New minor risk - Profitability

CymaBay Therapeutics, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Consensus revenue estimates fall by 15%

Price target increased by 8.5% to US$15.56

Insider notifies of intention to sell stock

Price target increased by 8.2% to US$14.67

New minor risk - Share price stability

Insider notifies of intention to sell stock

General Counsel notifies of intention to sell stock

Consensus revenue estimates fall by 40%

CymaBay Therapeutics, Inc. to Report Q1, 2023 Results on May 15, 2023

CymaBay Therapeutics, Inc. Appoints Harish Shantharam as Chief Financial Officer

Executive Officer notifies of intention to sell stock

Consensus revenue estimates increase by 24%

Price target increased by 11% to US$13.56

Price target increased by 8.1% to US$11.63

CymaBay Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $84.999785 million.

CymaBay Therapeutics (NASDAQ:CBAY) Has Debt But No Earnings; Should You Worry?

CymaBay Therapeutics Presents Additional Analyses from Clinical Studies of Seladelpar for Patients with Primary Biliary Cholangitis

CymaBay Therapeutics, Inc. Announces Executive Changes

CymaBay Therapeutics GAAP EPS of -$0.31 misses by $0.01

CymaBay Therapeutics, Inc. to Report Q2, 2022 Results on Aug 11, 2022

Cymabay Completes Enrollment for the Response Global Phase 3 Study Evaluating Seladelpar for Patients with Primary Biliary Cholangitis

Is CymaBay Therapeutics (NASDAQ:CBAY) Weighed On By Its Debt Load?

CymaBay: Long-Term Potential Based On Prior PBC Trial Results

CymaBay Therapeutics, Inc.(NasdaqGS:CBAY) dropped from Russell 2000 Dynamic Index

CymaBay Therapeutics, Inc. Presents Positive PBC Data at the International Liver Congress 2022

President recently bought US$100k worth of stock

CymaBay Therapeutics, Inc. Presents New Findings That Seladelpar Treatment of PBC Patients for Two Years Predicts Improved Transplant-Free Survival

Price target decreased to US$10.50

Insufficient new directors

CymaBay Therapeutics, Inc. Appoints Éric Lefebvre to the Audit Committee and the Nominating and Corporate Governance Committee of the Board

Is CymaBay Therapeutics (NASDAQ:CBAY) Using Debt In A Risky Way?